Anna K Blakney
Overview
Explore the profile of Anna K Blakney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
G Popova P, Lagace M, Tang G, Blakney A
Eur J Pharm Biopharm
. 2024 Mar;
198:114247.
PMID: 38462138
Messenger RNA (mRNA) and self-amplifying RNA (saRNA) vaccines against SARS-CoV-2 produced using in vitro transcription (IVT) were clinically approved in 2020 and 2022, respectively. While the industrial production of mRNA...
12.
Friesen J, Blakney A
J Gene Med
. 2024 Feb;
26(2):e3672.
PMID: 38380796
Ribonucleic acid (RNA) has emerged as one of the most promising therapeutic payloads in the field of gene therapy. There are many unique types of RNA that allow for a...
13.
Chen S, Blakney A
Curr Opin Biotechnol
. 2023 Dec;
85:103049.
PMID: 38118363
Ribonucleic acid therapeutics have advantages over biologics and small molecules, including lower safety risks, cheaper costs, and extensive targeting flexibility, which is rapidly fueling the expansion of the field. This...
14.
Casmil I, Huang C, Blakney A
Sci Rep
. 2023 Nov;
13(1):19050.
PMID: 37923834
Self-amplifying messenger ribonucleic acid (saRNA) provides extended expression of genes of interest by encoding an alphavirus-derived RNA replicase and thus is 2-3 times larger than conventional messenger RNA. However, quality...
15.
16.
Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines
Tregoning J, Stirling D, Wang Z, Flight K, Brown J, Blakney A, et al.
Mol Ther Nucleic Acids
. 2023 Jan;
31:29-42.
PMID: 36589712
To be effective, RNA vaccines require both translation and the induction of an immune response to recruit cells to the site of immunization. These factors can pull in opposite directions...
17.
Ly H, Daniel S, Soriano S, Kis Z, Blakney A
Mol Pharm
. 2022 May;
19(6):1892-1905.
PMID: 35604765
Lipid nanoparticles (LNPs) are the leading technology for RNA delivery, given the success of the Pfizer/BioNTech and Moderna COVID-19 mRNA (mRNA) vaccines, and small interfering RNA (siRNA) therapies (patisiran). However,...
18.
19.
20.
Webb C, Ip S, Bathula N, Popova P, Soriano S, Ly H, et al.
Mol Pharm
. 2022 Mar;
19(4):1047-1058.
PMID: 35238565
The coronavirus disease of 2019 (COVID-19) pandemic launched an unprecedented global effort to rapidly develop vaccines to stem the spread of the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2). Messenger...